Clinical Trials · NCT07184086
A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 80
- Start date
- Sep 2025
- Locations
- 2 sites, United States
- Primary endpoint
- Change in sleeping metabolic rate (SMR)